Research programme: premature ejaculation therapeutic - NeuroHealing

Drug Profile

Research programme: premature ejaculation therapeutic - NeuroHealing

Alternative Names: NH 02D

Latest Information Update: 10 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroHealing Pharmaceuticals
  • Class Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Premature ejaculation

Most Recent Events

  • 10 May 2013 Preclinical development is ongoing in USA
  • 10 May 2013 NeuroHealing Pharmaceuticals plans a phase II trial for Premature ejaculation in USA
  • 13 Apr 2009 Pharmacodynamics data from a preclinical trial in Premature ejaculation released by NeuroHealing Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top